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of treating minor bleeding adverse events related to VTEp was estimated as
USD$2679 and major bleeding was USD$5564. Similar estimations were found for
knee replacement events. CONCLUSIONS: The occurrence of VTE events related to
orthopedic surgery can significantly impact the costs of surgery, particularly given
that in Argentina the cost of hip replacement was estimated as USD $1959 and the
cost of knee replacement as USD $1193. One must therefore consider treatments
given for VTE prevention, as these therapies not only impact survival and quality of
life but can also substantially impact the efficient use of health care resources.
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OBJECTIVES:To evaluate the healthcare cost for themanagement of diabetes along
with other co-morbidities condition.METHODS: A cross-sectional study was con-
ducted in the Community setup of Warangal, India for a period of three months.
Only the educated Diabetic patients with other comorbidities were enrolled in the
study. The data collected were cost of medications, lab tests, consultation fee,
transportation cost. The average total healthcare cost was calculated based on the
previous two months expenses of each patient. RESULTS: A total of 100 patients
were evaluated in the study period. Out of 100 patients, majorities were in the age
group of 41-61 yrs 66 (66%) and also found to be higher in men 63 (63%) than in
women 37 (37%). Most of the patients were diabetes with hypertension, dyslipide-
mia. The average cost of medications per patient Rs. 1540 (72.81%), the average
laboratory cost per patient Rs. 350 (16.55%), the average doctors consultation fee
per patient Rs.175 (8.27%), the average transportation charges per patient Rs.50
(2.36%). The most common drugs prescribed in the study were Metformin, Gliben-
clamide, Gliclazide, Insulin, Ramipril, Amlodipine, Telmisartan, Metoprolol, Hy-
drochlorothiazide, Furosemide, Atorvastatin and Aspirin. The most common lab-
oratory test includes FBS/PPBS/RBS/HbA1C, lipid profiles, urine analysis, Hb,
Electrolytes and Sr.Creatinine. The average total healthcare cost for two months
was found to be Rs.2115 per patient. CONCLUSIONS: In summary, this is the first
Indian healthcare cost study conducted in the community setup. Diabetes imposes
an enormous economic burden on the healthcare system worldwide. This burden
will continue to increase in the next two decades. More prevention efforts and
resources are required to reduce this burden and to provide basic diabetes care in
the low- and middle-income countries.
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OBJECTIVES: The management of arterial hypertension in France starts with an
evaluation of the patient’s cardiovascular risk (function of age, sex, cholesterol
level, systolic blood pressure [SBP]) and if necessary, the prescription of a recom-
mended class among angiotensin converting enzyme (ACE)-inhibitors, angiotensin
receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCB) and thia-
zide diuretics. The objective of this study was to assess, for different patient’s
profiles, the cost-effectiveness of the recommended antihypertensive classes in
France. METHODS: A cohort of newly treated patients entered a Markov model,
using 1-month cycles in the first year, 1-year cycles until 10 years then lifetime
extrapolation of costs and benefits. The cohort was characterized by its cardiovas-
cular risk, evaluated via the France-specific Framingham equation. The risk reduc-
tions per class versus placebowere taken from themost recentmeta-analyses. The
probability to switch from monotherapy to bitherapy and tritherapy was depend-
ing on the achieved SBP (target 140mmHg) and the class-specific persistence. Na-
tional health care databases provided persistence and costs data. Discount rate
was 4% (costs and life-years). RESULTS: In low-risk patients (65-year-old female,
SBP 150mmHg), incremental cost-effectiveness vs. placebo ranged from 101€/life-
year gained (ACE-inhibitors followed by ACE-inhibitors/thiazides) to 7,722€/life-
year gained (beta-blockers followed by beta-blockers/CCB). Savings and extra ben-
efits vs. placebo were obtained in high-risk patients (74-year-old diabetic male,
smokers, SBP 180mmHg): up to 0.57 life-years gained with total costs reduced from
17,630€ to 15,403€ (ACE-inhibitors followed by ACE-inhibitors/CCB, least expensive
sequence) and 15,953€ (beta-blockers followed by beta-blockers/ARBs,most expen-
sive sequence). The classes rankingwas influenced by the persistence and diabetes
incidence. The differenceswere significant vs. placebo but not between the classes,
as per probabilistic sensitivity analysis. CONCLUSIONS: This lifetime model sug-
gests that all recommended anti-hypertensive drugs in France are very cost-effec-
tive versus placebo, and, in higher-risk patients, are even cost-saving with savings
comparable among the classes.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic disease charac-
terized by progressive elevation of pulmonary artery pressure and vascular resis-
tance, leading to right-sided heart failure and premature death. The objective
of the present research was to assess the clinical and economic aspects of current
oral treatments options for PAH, New York Heart Association (NYHA) functional
classes II and III, from the Brazilian Public Health Systemperspective.METHODS:A
literature review was conducted on the efficacy and safety of ambrisentan, bosen-
tan and sildenafil in patients diagnosed with PAH, in order to support the assump-
tion of clinical equivalence between the treatments and the development of a
cost-minimization analysis. The clinical outcome of interest was improvement in
the distance (in meters) walked in 6 minutes (6MWD). For the economic analysis,
direct medical costs were considered. Treatment, diagnostic, and procedure costs
were obtained from public price/reimbursement databases. Government acquisi-
tion prices were used for all drugs. Costs associated with adverse drug reactions
and treatment withdrawals were also considered. A one-year time-horizon was
used and all costs were presented in 2011 Brazilian currency (1BRL0.60USD).
RESULTS: There were no studies directly comparing any of the targeted agents.
Thus, an indirect comparison of placebo controlled trials of selected PAH therapies
was conducted. Standardized mean differences (SMD) between agents (over pla-
cebo) was calculated and the magnitude of effects between the comparators sug-
gested similar clinical efficacy over 12–16 weeks of treatment. Confidence intervals
of treatment effects overlapped substantially and supported the clinical assump-
tion. The total annual/monthly costs for the interventions were R$13,169.76/
R$1,097.48 for ambrisentan, R$13,226.86/R$1,102.24 for sildenafil, and R$30,227.70/
R$2,518.98 for bosentan. CONCLUSIONS: Ambrisentan was identified as the
alternativewith the lowest cost and similar clinical outcomes comparedwith other
selected therapies for treating patients diagnosed with PAH, NYHA functional
classes II and III, under the Brazilian public perspective.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus acetylsalicilic acid (ASA) in patients with Non-Valvular Atrial Fibrillation
(NVAF) from a private and public health care system perspective in Brazil.
METHODS: AMarkov model was built to compare DAB versus ASA to derive incre-
mental cost effectiveness ratio (ICER) of DAB based on a mixed treatment compar-
ison and a modified Delphi panel with Brazilian experts (local clinical practice
pattern on themanagement ofNVAFpatients). Themodel estimated the number of
ischaemic and haemorrhagic strokes, systemic embolisms, intracranial hemor-
rhages, transient ischaemic attacks, extracranial hemorrhages, minor bleeds and
acute myocardial infarctions associated with the respective treatments. To each
clinical event costs, disabilities and/or reduction in quality of life, and risk of death
were assigned. Only directmedical costs were considered and a discount rate of 5%
was assumed, according to Brazilian HTA guidelines. A probabilistic sensitivity
analysis was designed to assess uncertainty. RESULTS:Under both, the private and
public perspective, DAB was associated with additional 0.31 life years gained (LY),
additional 0.60 QALYs and demonstrated a lower incidence of intracranial events
versus ASP, resulting in a lower event costs (-R$ 1,057.84 and - R$ 3,006.07) and
follow up costs. The ICER for DAB versus ASAwas R$ 38,511.06/LY and R$ 31,379.80/
QALY from the public perspective and DAB was dominant from the private per-
spective. Sensitivity analyses confirmed the cost-effectiveness of DAB.
CONCLUSIONS: Findings suggest that DAB can be cost-effective for stroke preven-
tion when used instead of ASA in NVAF patients in Brazil, given that DAB was
dominant in the private sector and ICERS were below the threshold of other tech-
nologies reimbursed in the public health care sector.
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OBJECTIVES: Although medication advice is a key component in cardiac rehabili-
tation (CR) program, little is known about its effectiveness on patient medication
use behaviors. This project aimed to assess the cost-effectiveness of CR programon
patient adherence to cardiac medication and the number of hospitalization
avoided. METHODS: Using MarketScan® Medicaid database, patients with acute
myocardial infarction (AMI) were targeted. By using propensity scores, 471 patients
receiving CR programs during 2003- 2007were 1:1matchedwith 471 controls (with-
out CR) on patient demographics, comorbidities and healthcare costs before the CR
started. The economic perspective was that of third-payer sector so only direct
medical costs were included (costs attributed to CR program and the use of cardiac
specific medical services and medications). Main outcomes were patient adher-
ence to cardiacmedicationmeasured byMedication Possession Ratio and the num-
ber of cardiac related hospitalization. The cardiac medications studied were 1
selective-blockers, angiotensin converting enzyme inhibitors and angiotensin re-
ceptor blockers. The outcomes were estimated every 4 months during 1-year fol-
low-up. Cost-effectiveness of CR programwas determined by the incremental cost-
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effectiveness ratio (ICER). Bootstrapping technique was applied for assessing
uncertainty in cost-effectiveness analyses. The robustness of findings was tested
in sensitivity analyses. RESULTS:Although there were no significant differences in
medication adherence and hospitalization outcomes between two groups, patients
in CR programs had a gradually improved medication adherence and lower hospi-
talization over time. Mean annual costs (2003 value) were $3172 and $2092 per
patient for CR group and control group, respectively. The ICER was $538 for 1%
improvement inmedication adherence and $1080 for an additional hospitalization
avoided. CONCLUSIONS: CR programs offered benefits of improving medication
adherence and reducing hospitalization over time although it was costly in the
beginning of its provision. Trade-off of increase in costs for the increase in benefits
should be considered.
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OBJECTIVES: To analyze the cost-effectiveness of treating hypertensive patients
with azilsartan medoxomil and chlorthalidone fixed dose combination (AZL-M/
CLD FDC) therapy compared with other angiotensin receptor blocker (ARB) and
hydrochlorothiazide (HCT) combinations commonly available in the US market.
METHODS:AMarkov Cohort Simulation approachwas utilized. Simulated patients
start in a hypertensive state and are followed over multiple time periods as they
transition betweenmutually exclusive health states. Cost per Quality Adjusted Life
Year (Cost/QALY) and Incremental Cost-effectiveness Ratios (ICERs) are calculated
over all possible dose combinations. Cardiovascular disease (CVD) riskswere based
on the Framingham risk equations. FDCs of HCT and eight ARBs commonly used in
the US market (Atacand HCT, Avalide, Benicar HCT, Hyzaar, Diovan HCT, generic
Losartan HCT, Micardis HCT and Teveten HCT) were included in the analyses.
RESULTS: Results suggest that AZL-M/CLD FDC is less expensive and more effec-
tive in lowering BP versus all branded ARB/HCT FDC comparators. When consider-
ing average costs and the CVD risks based on the Framingham risk equations for all
therapies over a five year time horizon, AZL-M/CLD FDC would remain the least
expensive andmost effective branded ARB/Diuretic FDC therapy up to a 23.5% unit
cost increase with the average office SBP reduction of -22.3% and up to 18.1% unit
cost increase with the 24-hour ambulatory BP reduction of -17.0%. CONCLUSIONS:
AZL-M/CLD FDC is predicted to be less expensive and more effective in reducing
blood pressure and cardiovascular risk when compared to all branded ARB/HCT
FDC comparators during a five year time horizon.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran compared to War-
farin in non-complicated atrial fibrillation in Colombia.METHODS:We developed
a Markov model to represent the health states of atrial fibrillation and its compli-
cations;6 health states and 2 transitional states were considered,including dis-
abling and non-disabling stroke, myocardial infarction, pulmonary embolism and
death. Major andminor hemorrage were considered transitory in the model. Prob-
abilities were derived from published clinical trials. Resource use was estimated
from the Colombian Society of Cardiology guidelines and validated to adjust to
usual practice. Directmedical costswere derived fromdifferent sources (public and
private) and indirect costs (predicted wages lost and transportation costs) were
obtained from the most recent National Health Survey. Utilities were obtained
from a systematic literature review. Two separate analysis, payer and societal
perspective, were performed in a 20-year horizon. Maximum andminimum values
of effectiveness and resource use were included in the sensitivity analysis. The
results were discounted at 3% annually. RESULTS: After 20 years of follow up,
discounted direct medical costs accounted for USD$70,500 for Warfarin and
$78,840 and $79,860 for 150mg and 110mg of Dabigatran, respectively.When taking
into account indirect costs,Warfarin increased their costs by 13%while Dabigatran
costs were increased by 9%. Estimated life years for Dabigatran were higher (9.40
and 9.29 for 150mg and 110mg, respectively) as well as the QALYs (8.48, 8.39) than
for Warfarin 9.09 LY and 8.12 QALYs. The calculated ICER was $23,760 and $34,690
per additional QALY when taking into account direct costs and even lower when
considering indirect costs. CONCLUSIONS: In Colombia, the use of Dabigatran for
the management of non-complicated atrial fibrilation compared to Warfarin in-
creases years of life and QALYs. Assuming a similar willingnes-to-pay as for other
cardiovascular interventions, dabigatran is a cost-effective intervention.
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OBJECTIVES: To assess the cost-effectiveness of urapidil compared with standard
treatment of hypertension urgenciesMETHODS: A decision tree was used to sim-
ulate the effects of urapitil and standard therapy drugs such as captopril, clonidine,
nifedipine, metoprolol, magnesium sulphate, furosemide, enalaprilat. Standard
therapy drugs were revealed after observational study of prehospital treatment of
hypertension crisis. The efficacy of drugs was obtained from clinical trials, while
medical care costs were estimated from standard of treatment of hypertension
urgencies developed and published by Ministry of public health. A cost-effective-
ness ratio of urapidil was compared with other drugs. At the last stage double
phase sensitivity analysis was conducted. RESULTS: A CER of urapidil was the
lowest (1942.89 RUB/64.73$) in comparison to another drugs (captopril-1966.34
RUB/65.53$; metoprolol-2191.43 RUB/73.03$; enalaprilat - 2443.52 RUB/81.45$; ni-
fedipine-2485.71 RUB/82.83$; furosemide-2505.53 RUB/83.5$; clonidine-2558.12
RUB/85.26$; ; magnesium sulphate -2932.92 RUB/97.73$). Sensitivity analysis dem-
onstrated stability of results, changing cost of hospitalization and cost of urapidil
the advantage of urapidil from the position of “cost-effectiveness” was still
obviously. CONCLUSIONS: Treatment of hypertension urgencies with urapidil is a
dominated alternative from the perspective of the health economics.
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OBJECTIVES: To compare the costs and effectiveness of dabigatran etexilate with
current standard treatment in patients with non-valvular atrial fibrillation (NVAF),
from the Slovakian health care system perspective. METHODS: A previously pub-
lishedMarkov cohortmodelwas adopted to estimate the outcomes of patientswith
dabigatran (150mg BID, 110mg BID) in its labelled indication during their lifetime
for the following health states: ischemic and haemorrhagic stroke, transient isch-
emic attack, systemic embolism, intracranial and extracranial haemorrhage, acute
myocardial infarction, minor bleeds and death. Data on event rates and patient
quality of life associated with different health states and patient survival time was
based on the RE-LY trial and the literature. The base-case consisted of a cohort of
patients with NVAF, CHADS21 and no contraindications to anticoagulation ther-
apy. Themodelled consequences of the clinical eventswere costs, disability and/or
reduction in quality of life and death. Data on resource use associated with patient
management and different events were estimated using a Slovakian expert panel,
while unit prices were collected from the official sources update 2011. One-way
sensitivity analyses was used on all relevant variables to test the robustness of the
analysis. RESULTS: The dabigatran group had more life years and QALYs gained
compared to standard treatment (warfarin, aspirin, clopidogrel and no treatment);
these gains were primarily driven by a lower incidence of the intracranial events
and systemic embolism. A cohort of 5,000 patients treated with dabigatran during
their lifetime gained 40,238QALYs (standard: 38,178QALYs)with incremental costs
of €35.9mill (standard: €37.3mill). The incremental cost-effectiveness ratio (ICER) of
dabigatran versus standard treatment was estimated at €17,437, below the Slovak-
ian acceptable threshold (€18,000 per QALY gained). The sensitivity analysis con-
sistently demonstrated the cost-effectiveness of dabigatran. CONCLUSIONS: Dab-
igatran represents a cost-effective treatment for preventing strokes in patients
with NVAF in Slovakia.
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OBJECTIVES: Dabigatran was approved in the United States to reduce the risk of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Dabigatran has several potential advantages over the current standard of care
(warfarin), including a generally better side effect profile, fewer drug interactions,
and no international normalized ratio (INR)monitoring, but it is considerablymore
expensive. The objective of this analysis was to determine the cost-effectiveness of
dabigatran versus warfarin for AF in a Medicare population.METHODS: A Markov
model was used to simulate outcomes for patients aged 65 with AF and a (CHADS2)
congestive heart failure, hypertension, age, diabetes, prior stroke [doubled] score
1. A 5-year time horizon and a managed care perspective were employed in this
analysis. Data comparing the clinical performance of dabigatran and warfarin was
derived from the RE-LY trial. Quality-adjusted life-years (QALYs) were used to as-
sess outcomes and utility weights were obtained from systematic reviews. Direct
medical costs associated with complications from AF were based on hospitaliza-
tion costs for diagnostic-related groups and reported in U.S. 2011 dollars. RESULTS:
Over a 5-year period, the incremental cost-effectiveness ratio (ICER) for dabigatran
150 mg was $26,551 per QALY compared to warfarin. The ICER was most sensitive
to the utility associatedwith thewell state for each of the alternatives aswell as the
price of dabigatran, warfarin, and INR monitoring needed for warfarin therapy. In
probabilistic analyses, dabigatran was cost-effective in 91% of simulations at a
$50,000/QALY threshold. CONCLUSIONS: Prescribing dabigatran increases quality-
adjusted life expectancy for AF patients at a cost considered acceptable by Amer-
ican payers.
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